Compare iShares Global Clean Energy ETF (ICLN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Mesoblast Limited — how do they compare? iShares Global Clean Energy ETF trades at $17.23 (market cap $2.27B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: iShares Global Clean Energy ETF is the larger of the two by market cap, and iShares Global Clean Energy ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and Mesoblast Limited for 14 Days on average.
| ICLN | MESO | |
|---|---|---|
Market Cap | $2.27B | $1.75B |
Volume | 6,845,064 | 239,027 |
52-Week High | $23.75 | $20.96 |
52-Week Low | $15.78 | $13.19 |
Typical Hold Time | 87 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF's financial ratios are unavailable in the provided data, but recent news highlights its focus on global clean energy with 105 holdings and a 0.38% expense ratio. It faces volatility, with a 57.2% maximum drawdown noted in comparisons against traditional energy ETFs.
The outlook for ICLN is mixed; geopolitical tensions and global renewable energy investments provide tailwinds, but high volatility and competition from fossil fuel ETFs pose risks. Investors should weigh its growth potential against expense ratios and performance consistency in the evolving energy sector.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
